review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1007/BF00204625 |
P698 | PubMed publication ID | 8362342 |
P2093 | author name string | A W Ford-Hutchinson | |
P2860 | cites work | Identification of a human gamma-glutamyl cleaving enzyme related to, but distinct from, gamma-glutamyl transpeptidase | Q24293328 |
Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis | Q24299373 | ||
Evaluation of the role of conserved His and Met residues among lipoxygenases by site-directed mutagenesis of recombinant human 5-lipoxygenase | Q28242585 | ||
Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects | Q68293935 | ||
Leukotriene B4 potentiates the expression and release of Fc epsilon RII/CD23, and proliferation and differentiation of human B lymphocytes induced by IL-4 | Q68484069 | ||
Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist | Q68487207 | ||
The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man | Q68518136 | ||
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air | Q68613879 | ||
Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist | Q69343462 | ||
The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects | Q69838847 | ||
Leukotriene A3. A poor substrate but a potent inhibitor of rat and human neutrophil leukotriene A4 hydrolase | Q70097113 | ||
Human 5-lipoxygenase contains an essential iron | Q70163897 | ||
Inhibition of leukotriene C and leukotriene D biosynthesis | Q72430373 | ||
Specific binding of leukotriene B4 to receptors on human polymorphonuclear leukocytes | Q72940777 | ||
Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses | Q72963149 | ||
Slow reacting substance and related compounds | Q79357743 | ||
Human leukotriene C4 synthase expression in dimethyl sulfoxide-differentiated U937 cells | Q28264329 | ||
A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP | Q28302244 | ||
Purification of human leukotriene C4 synthase from dimethylsulfoxide-differentiated U937 cells | Q28317185 | ||
Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist | Q28322631 | ||
Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes | Q28342930 | ||
Leukotriene C: a slow-reacting substance from murine mastocytoma cells | Q33972104 | ||
Molecular cloning of a cDNA coding for human leukotriene A4 hydrolase. Complete primary structure of an enzyme involved in eicosanoid synthesis. | Q34186608 | ||
Liberation of histamine and formation of lysocithin-like substances by cobra venom | Q34568156 | ||
Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients | Q36241039 | ||
Human T-lymphocyte subset specificity of the regulatory effects of leukotriene B4 | Q36270108 | ||
Heterogeneity of human polymorphonuclear leukocyte receptors for leukotriene B4. Identification of a subset of high affinity receptors that transduce the chemotactic response | Q36348698 | ||
Leukotriene D: a slow reacting substance from rat basophilic leukemia cells | Q36363644 | ||
Leukotriene B4 in inflammation. | Q37873024 | ||
Leukotriene receptor antagonists as potential therapeutic agents | Q38272493 | ||
Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma | Q41085264 | ||
Reduced Allergen-Induced Nasal Congestion and Leukotriene Synthesis with an Orally Active 5-Lipoxygenase Inhibitor | Q41137843 | ||
Inhibition of human leukocyte 5-lipoxygenase by a 4-hydroxybenzofuran, L-656,224. Evidence for enzyme reduction and inhibitor degradation | Q41182690 | ||
Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. | Q41199570 | ||
A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma | Q41273463 | ||
Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor | Q42119720 | ||
Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma | Q42126419 | ||
Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction | Q42161966 | ||
L-649,923, sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)- gamma-hydroxy-beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist | Q42206200 | ||
The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs). | Q42272808 | ||
The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. | Q43648861 | ||
L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor | Q45227226 | ||
Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571 | Q46209751 | ||
Inhibition of endogenous leukotriene-mediated lung anaphylaxis in guinea pigs by a novel receptor antagonist ONO-1078. | Q46233704 | ||
Leukotriene B: a potential mediator of inflammation | Q46329837 | ||
FLAP: a novel drug target for inhibiting the synthesis of leukotrienes | Q46393647 | ||
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist | Q46786376 | ||
Structure of slow-reacting substance of anaphylaxis from guinea-pig lung | Q46852072 | ||
5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors | Q46967003 | ||
MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human | Q49122118 | ||
L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)- propylsulfonyl]-gamma-oxo-benzenebutanoate: a leukotriene D4 receptor antagonist. | Q53884882 | ||
Leukotrienes: potent mediators of airway constriction. | Q53905232 | ||
The effect of an oral leukotriene D4 antagonist L-649,923 on the response to inhaled antigen in asthma. | Q54407306 | ||
Identification and isolation of a membrane protein necessary for leukotriene production | Q59059824 | ||
Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes | Q59077242 | ||
Leukotriene B4 induces human suppressor lymphocytes | Q67253442 | ||
MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes | Q67267224 | ||
Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors | Q67492647 | ||
5-lipoxygenase inhibitory activity of zileuton | Q67914330 | ||
Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma | Q67995623 | ||
Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition | Q68129408 | ||
Maximal airway narrowing to inhaled leukotriene D4 in normal subjects. Comparison and interaction with methacholine | Q68193088 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 37-50 | |
P577 | publication date | 1993-01-01 | |
P1433 | published in | Seminars in Immunopathology | Q15724576 |
P1476 | title | Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions | |
P478 | volume | 15 |
Search more.